Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3) [PDF]
Modern Rheumatology, 2022 OBJECTIVES: To evaluate the efficacy and safety of filgotinib for Japanese patients with rheumatoid arthritis (RA) and limited or no prior methotrexate (MTX) exposure.
Tatsuya Atsumi +2 more
exaly +2 more sources
Related searches:
Filgotinib as rheumatoid arthritis therapy
Drugs of Today, 2021Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and progressive disability when inflammation cannot be sufficiently controlled. Despite treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs), up to 30% of RA patients do not reach or fail to ...
A, Becciolini +6 more
openaire +2 more sources
Filgotinib in rheumatoid arthritis
Expert Review of Clinical Immunology, 2022Rheumatoid Arthritis (RA) remains a challenge for rheumatologists and patients despite implementation of intensive treat-to-target strategies in shared decision with patients and an increasing availability of drugs. Janus kinase inhibitors (JAKi) are a new generation of oral targeted drugs. Filgotinib preferentially inhibits JAK1 and is the latest JAKi
openaire +2 more sources
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial [PDF]
Lancet, The, 2018 Background: At present, biological disease-modifying anti-rheumatic drugs (DMARDs) are the only treatment recommended for patients with ankylosing spondylitis who have not responded to first-line treatment with non-steroidal anti-inflammatory drugs ...
Desirée Van Der Heijde +2 more
exaly +3 more sources
Filgotinib for the treatment of Crohn’s disease
Expert Opinion on Investigational Drugs, 2018Inflammatory bowel diseases, such as Crohn's disease (CD) and ulcerative colitis (UC), are widespread diseases (with an estimated 2.2 million Europeans affected), and even populations previously considered 'low risk' (such as Japan and India) are witnessing an increasing incidence.
Stéphane Paul, Xavier Roblin
exaly +5 more sources
Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights
Expert Review of Clinical Pharmacology, 2021Rheumatoid arthritis (RA) is a chronic autoimmune disease, whose natural course has been deeply modified thanks to the development of new therapeutic approaches. The Janus kinase inhibitors (Jakinibs) represent the newest class of drugs introduced for treating RA.
Maria Gabriella Raimondo +5 more
openaire +2 more sources
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial [PDF]
Lancet, The, 2018 BACKGROUND: The Janus kinase 1 (JAK1) pathway has been implicated in the pathogenesis of psoriatic arthritis. We aimed to investigate the efficacy and safety of filgotinib, a selective JAK1 inhibitor, for the treatment of psoriatic arthritis.
Philip J Mease +2 more
exaly +1 more source
Filgotinib for the Treatment of Refractory Collagenous Colitis
Journal of Crohn's and Colitis, 2023Tomoyoshi Shibuya, Akihito Nagahara
openaire +2 more sources
Filgotinib for ulcerative colitis
Nature Reviews Gastroenterology & Hepatology, 2021openaire +2 more sources